BioMarin Pharmaceutical (NASDAQ:BMRN) Announces Earnings Results, Misses Estimates By $1.04 EPS

BioMarin Pharmaceutical (NASDAQ:BMRN) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.80 by ($1.04), Briefing.com reports. BioMarin Pharmaceutical had a return on equity of 9.53% and a net margin of 16.82%.The company had revenue of $874.57 million for the quarter, compared to analyst estimates of $834.32 million. During the same quarter in the previous year, the firm posted $0.92 EPS. BioMarin Pharmaceutical’s quarterly revenue was up 17.0% on a year-over-year basis.

Here are the key takeaways from BioMarin Pharmaceutical’s conference call:

• BioMarin reported strong 2025 results with total revenue up 13% to $3.22 billion, Q4 revenue of $875 million, non‑GAAP EPS of $3.15 and operating cash flow of $828 million (up 45%), and provided 2026 guidance (ex‑Amicus) of $3.325–$3.425 billion revenue and non‑GAAP EPS of $4.95–$5.15 with ~40% organic operating margin.
• The announced Amicus acquisition (expected to close in Q2 2026) is positioned to add Galafold, Pombiliti and Opfolda, management secured ~$3.7 billion of financing and expects the deal to materially uplift revenue and patient reach after close despite modest 2026 dilution.
• BioMarin withdrew Roctavian from the market and booked ~$240 million of Q4 GAAP special items, including an inventory write‑off (about half) that is not excluded from non‑GAAP, pressuring reported GAAP results.
• Voxzogo continues driving growth (26% FY to $927 million, ~73% ex‑US, >5,000 patients treated); management plans a full FDA approval submission (adult height and broader outcomes) and is pursuing a hypochondroplasia expansion that could add new indications.
• Revenue cadence is uneven—Q4 benefited from an unusual ~$30 million government order and stocking increases that are unlikely to repeat, and management expects Q1 2026 to be the lowest quarter with some market access renegotiations potentially weighing on near‑term growth.

BioMarin Pharmaceutical Stock Down 1.8%

Shares of BMRN opened at $62.92 on Tuesday. The firm has a market capitalization of $12.09 billion, a P/E ratio of 23.65, a P/E/G ratio of 0.70 and a beta of 0.26. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.10 and a current ratio of 4.83. The company has a 50-day simple moving average of $58.31 and a 200-day simple moving average of $56.04. BioMarin Pharmaceutical has a 52 week low of $50.76 and a 52 week high of $73.51.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of BioMarin Pharmaceutical from $70.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Wedbush reaffirmed an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Tudor Pickering set a $88.00 price target on BioMarin Pharmaceutical in a research report on Monday, November 3rd. Piper Sandler reduced their price objective on BioMarin Pharmaceutical from $122.00 to $84.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Finally, Morgan Stanley cut their target price on shares of BioMarin Pharmaceutical from $104.00 to $98.00 and set an “overweight” rating for the company in a research report on Tuesday, October 28th. Fourteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $87.65.

Institutional Trading of BioMarin Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its stake in BioMarin Pharmaceutical by 11.5% during the first quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock worth $266,000 after purchasing an additional 388 shares during the period. Empowered Funds LLC boosted its stake in BioMarin Pharmaceutical by 207.4% in the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 8,112 shares in the last quarter. Focus Partners Wealth raised its stake in BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in BioMarin Pharmaceutical by 33.0% in the second quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 1,102 shares in the last quarter. Finally, Invesco Ltd. raised its position in BioMarin Pharmaceutical by 23.5% in the 2nd quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company’s stock worth $34,017,000 after purchasing an additional 117,617 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical News Summary

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Announced definitive agreement to acquire Amicus Therapeutics, bringing marketed assets (Galafold) and late‑stage programs (Pombiliti + Opfolda) that management says will materially diversify and accelerate revenue growth; expected close Q2’26. PR Newswire: Amicus Acquisition
• Positive Sentiment: Underlying revenue momentum: Q4 total revenues up ~17% Y/Y and full‑year 2025 revenues rose ~13% to $3.2B, with VOXZOGO showing strong double‑digit growth—key for near‑term top‑line expansion. PR Newswire: Q4/FY Results
• Positive Sentiment: Analyst backing: TD Cowen kept a Buy rating and $120 PT citing the quarter and strategic deal; Bank of America reiterated Buy (cut PT to $97) but highlights pipeline upside that offsets competitive pressures on VOXZOGO. TipRanks: TD Cowen TipRanks: BofA
• Neutral Sentiment: 2026 guidance excludes any post‑close contribution from Amicus: company gave revenue guidance of roughly $3.3–$3.4B (vs. consensus ~ $3.4B), so the near‑term outlook may look conservative until the deal closes and contributions are modeled. PR Newswire: Guidance
• Neutral Sentiment: Mixed earnings signal: multiple outlets highlight revenue beats, but reported EPS figures and their treatment (GAAP vs. adjusted, one‑offs) vary across publications — investors should review the earnings slides and call transcript for reconciliation. Zacks: Q4 Beat Seeking Alpha: Call Transcript
• Negative Sentiment: Market reaction and near‑term pressure: shares have moved lower as investors digest mixed EPS metrics, the conservative guidance baseline (pre‑Amicus), and potential integration uncertainty tied to the Amicus transaction. Investing.com: Shares Edge Lower

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.